Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry

Clinical Biochemistry

Volumn 45, Issue 4-5, 2012, Pages 331-338

  Végvári, Ákos ^a   Rezeli, Melinda ^a   Sihlbom, Carina ^b   Häkkinen, Jari ^a   Carlsohn, Elisabet ^b   Malm, Johan ^a   Lilja, Hans ^a,c   Laurell, Thomas ^a,d   Marko Varga, György ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Dongguk University   (South Korea)

Author keywords

ESI LTQ FT ICR; Infertility; Isoform; MALDI LTQ Orbitrap XL; Prostate specific antigen; Seminal plasma

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GEL; HUMAN; MALE INFERTILITY; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; SEMINAL PLASMA; WESTERN BLOTTING; ZYMOGRAPHY;

ADULT; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CLUSTER ANALYSIS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; INFERTILITY, MALE; ISOENZYMES; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PEPTIDE MAPPING; PROSTATE-SPECIFIC ANTIGEN; PROTEOLYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SEMEN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84857655838     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.11.018     Document Type: Article

References (36)

1. Lilja H., Ulmert D., Bjork T., Becker C., Serio A.M., Nilsson J.A., et al. Long-term prediction of prostate cancer up to 25years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50years. J Clin Oncol 2007, 25:431-436.
2. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0ng per milliliter. N Engl J Med 2004, 350:2239-2246.
3. Schröder F.H., Hugosson J., Roobol M.J., Tammela T.L.J., Ciatto S., Nelen V., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
4. Lundwall Å., Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 1987, 214:317-322.
5. Rittenhouse H.G., Finlay J.A., Mikolajczyk S.D., Partin A.W. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998, 35:275-368.
6. Canto E.I., Singh H., Shariat S.F., Lamb D.J., Mikolajczyk S.D., Linton H.J., et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 2004, 63:905-910.
7. Mikolajczyk S.D., Millar L.S., Wang T.J., Rittenhouse H.G., Wolfert R.L., Marks L.S., et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000, 55:41-45.
8. Darson M.F., Pacelli A., Roche P., Rittenhouse H.G., Wolfert R.L., Saeid M.S., et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999, 53:939-944.
9. Watt K.W.K., Lee P.-J., M'Timkulu T., Chan W.-P., Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986, 83:3166-3170.
10. Lövgren J., Rajakoski K., Karp M., Lundwall Å., Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 1997, 238:549-555.
11. Takayama T.K., Fujikawa K., Davie E.W. Characterization of the precursor of prostate-specific antigen. J Biol Chem 1997, 272:21582-21588.
12. Emami N., Diamandis E.P. Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. J Biol Chem 2008, 283:3031-3041.
13. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 1985, 76:1899-1903.
14. Lilja H., Oldbring J., Rannevik G., Laurell C.B. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 1987, 80:281-285.
15. Pezzato E., Sartor L., Dell Aica I., Dittadi R., Gion M., Belluco C., et al. Prostate carcinoma and green tea: PSA-triggered basement membrane degradation and MMP-2 activation are inhibited by (-)epigallocatechin-3-gallate. Int J Cancer 2004, 112:787-792.
16. Christensson A., Lilja H. Complex-formation between protein-C inhibitor and prostate-specific antigen in-vitro and in human semen. Eur J Biochem 1994, 220:45-53.
17. Espana F., Gilabert J., Estelles A., Romeu A., Aznar J., Cabo A. Functionally active protein-C inhibitor plasminogen-activator inhibitor-3 (PCI/PAI-3) is secreted in seminal-vesicles, occurs at high-concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 1991, 64:309-320.
18. Laurell M., Christensson A., Abrahamsson P.A., Stenflo J., Lilja H. Protein-C inhibitor in human-body fluids - seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive-system. J Clin Invest 1992, 89:1094-1101.
19. Lilja H., Ulmert D., Vickers A.J. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008, 8:268-278.
20. Walsh T.J., Schembri M., Turek P.J., Chan J.M., Carroll P.R., Smith J.F., et al. Increased risk of high-grade prostate cancer among infertile men. Cancer 2010, 116:2140-2147.
21. Armbruster D.A. Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 1993, 39:181-195.
22. Bélanger A., van Halbeek H., Graves H.C.B., Grandbois K., Stamey T.A., Huang L., et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995, 27:187-197.
23. Zhang W.-M., Leinonen J., Kalkkinen N., Dowell B., Stenman U.-H. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995, 41:1567-1573.
24. Tabares G., Radcliffe C.M., Barrabes S., Ramirez M., Aleixandre R.N., Hoesel W., et al. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 2006, 16:132-145.
25. Hilz H., Noldus J., Hammerer P., Buck F., Lück M., Huland H. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. Eur Urol 1999, 36:286-292.
26. Isono T., Tanaka T., Kageyama S., Yoshiki T. Structural diversity of cancer-related and non-cancer-related prostate-specific antigen. Clin Chem 2002, 48:2187-2194.
27. Okada T., Sato Y., Kobayashi N., Sumida K., Satomura S., Matsuura S., et al. Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. Biochim Biophys Acta 2001, 1525:149-160.
28. Prakash S., Robbins P.W. Glycotyping of prostate specific antigen. Glycobiology 2000, 10:173-176.
29. Mikolajczyk S.D., Grauer L.S., Millar L.S., Hill T.M., Kumar A., Rittenhouse H.G., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997, 50:710-714.
30. Noldus J., Chen Z., Stamey T.A. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997, 158:1606-1609.
31. Végvári Á., Rezeli M., Welinder C., Malm J., Lilja H., Marko-Varga G., et al. Identification of prostate specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. J Proteomics 2010, 73:1137-1147.
32. Dickson E.F., Pollak A., Diamandis E.P. Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. Pharmacol Ther 1995, 66:207-235.
33. Pettersson K., Piironen T., Seppala M., Liukkonen L., Christensson A., Matikainen M.T., et al. Free and complexed prostate-specific antigen (PSA) - in-vitro stability, epitope map, and development of immunofluorimetric assays for specific and sensitive detection of free PSA and PSA-alpha(1)-antichymotrypsin complex. Clin Chem 1995, 41:1480-1488.
34. Häkkinen J., Vincic G., Månsson O., Wårell K., Levander F. The Proteios software environment: an extensible multiuser platform for management and analysis of proteomics data. J Proteome Res 2009, 8:3037-3043.
35. Levander F., Krogh M., Wårell K., Gärdén P., James P., Häkkinen J. Automated reporting from gel-based proteomics experiments using the open source Proteios database application. Proteomics 2007, 7:668-674.
36. Kersey P.J., Duarte J., Williams A., Karavidopoulou Y., Birney E., Apweiler R. The international protein index: an integrated database for proteomics experiments. Proteomics 2004, 4:1985-1988.